KORU Medical Systems, Inc. (KRMD) – What Are Researchers Saying About This Stock?

KORU Medical Systems, Inc. (NASDAQ:KRMD) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of equities analysts recently weighed in on the company. Wall Street Zen cut KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings lowered KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 29th. Zacks Research cut shares of KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 30th. Finally, Craig Hallum reiterated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research report on Thursday, August 6th.

Insider Buying and Selling at KORU Medical Systems

In other KORU Medical Systems news, insider Adam Kalbermatten acquired 32,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was bought at an average price of $3.16 per share, with a total value of $101,120.00. Following the purchase, the insider owned 394,017 shares of the company’s stock, valued at approximately $1,245,093.72. This trade represents a 8.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 18.50% of the company’s stock.

Hedge Funds Weigh In On KORU Medical Systems

A number of large investors have recently added to or reduced their stakes in KRMD. BlackRock Inc. bought a new stake in KORU Medical Systems in the second quarter valued at approximately $11,039,000. Meros Investment Management LP bought a new stake in shares of KORU Medical Systems during the 2nd quarter valued at $3,190,589. Royal Bank of Canada boosted its holdings in shares of KORU Medical Systems by 77.3% during the 1st quarter. Royal Bank of Canada now owns 235,804 shares of the company’s stock valued at $1,019,000 after buying an additional 102,800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of KORU Medical Systems in the 2nd quarter worth about $642,000. Finally, Squarepoint Ops LLC lifted its position in KORU Medical Systems by 858.0% during the 2nd quarter. Squarepoint Ops LLC now owns 124,755 shares of the company’s stock valued at $524,000 after acquiring an additional 111,733 shares during the period. Hedge funds and other institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Stock Performance

KRMD traded up $0.06 during trading on Friday, reaching $3.09. The stock had a trading volume of 105,444 shares, compared to its average volume of 167,885. The business has a 50-day moving average of $3.12 and a 200-day moving average of $3.97. KORU Medical Systems has a one year low of $2.86 and a one year high of $6.61. The stock has a market cap of $141.92 million, a PE ratio of -77.25 and a beta of 0.47.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.62 million. KORU Medical Systems had a negative return on equity of 10.63% and a negative net margin of 4.03%. Equities research analysts forecast that KORU Medical Systems will post -0.02 EPS for the current fiscal year.

About KORU Medical Systems

KORU Medical Systems, Inc develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems.

KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.